本文へ移動
cccskills
無料GitHub で公開

endo-inpatient-cgm-continuation-vs-discontinuation

Recommends continuing a patient’s personal continuous glucose monitor (CGM) in the hospital with or without algorithm-driven insulin pump (ADIP) therapy rather than discontinuing it for individuals already using CGM outpatient. Use when deciding whether to maintain personal CGM during admission or when a patient requests to keep their device, particularly in those at high risk for hypoglycemia.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md3.0 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Continuation of Personal CGM in Inpatient Setting vs Discontinuation for Patients Already Using CGM

STEP 1 — Gather Information

Confirm outpatient personal CGM use (device model, supplies, patient proficiency), assess hypoglycemia risk factors (history of severe hypoglycemia, impaired awareness, renal/hepatic dysfunction), screen for contraindications (extensive skin infection, hypoperfusion, vasoactive pressor therapy, need for MRI/procedures requiring sensor removal), and verify patient has access to backup supplies and point-of-care blood glucose (POC-BG) for validation.

STEP 2 — Rule In / Rule Out

Is the patient currently using personal CGM outpatient and free of absolute contraindications to inpatient CGM use? If yes, proceed to stratification; if no, consider discontinuation and transition to hospital-managed glucose monitoring.

STEP 3 — Classify or Stratify

Stratify by hypoglycemia risk: high risk (prior severe hypoglycemia requiring assistance, impaired awareness, CKD stage 3‑5, hepatic failure) vs lower risk; both groups may continue CGM but high‑risk patients benefit most from hybrid CGM + POC‑BG approach.

STEP 4 — Decide

For patients who pass the rule‑in, continue personal CGM in the inpatient setting with a hybrid approach: use CGM for trend alerts but obtain confirmatory POC‑BG before any insulin or glucose‑modifying therapy adjustments; if contraindications arise, discontinue personal CGM and rely on hospital POC‑BG or institutional CGM protocols.

Clinical Guardrails / Mimics / Pitfalls

Do not use CGM values alone to direct insulin dosing; always validate with POC‑BG prior to therapy changes. Avoid CGM in patients with extensive skin infection, hypoperfusion, vasopressor therapy, or undergoing MRI/procedures that require sensor removal. Remember inpatient CGM use is not FDA‑approved but operates under enforcement discretion; ensure staff training, have clear protocols for sensor removal/re‑application, and maintain access to SMBG/CGM supplies.

Concrete Clinical Example

A 22‑year‑old with type 1 diabetes using a Dexcom G6 admits for elective appendectomy; she has no skin infection, is not on pressors, and requests to keep her CGM. The team confirms her supplies, educates nursing on trend alerts, and obtains POC‑BG checks before each insulin dose adjustment, continuing her personal CGM throughout the stay.

Source: Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, DOI: 10.1210/clinem/dgac596

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する